PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT2766021

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
LUNAN PHARMACEUTICAL GROUP CORPORATION	02/14/2014
FAGEN BIOMEDICAL INC. CHONGQING	02/14/2014

RECEIVING PARTY DATA

LUNAN PHARMACEUTICAL GROUP CORPORATION	
NO. 209, HONGQI ROAD	
LINYI CITY	
CHINA	
276006	
SHANDONG NEW TIME PHARMACEUTICAL CO., LTD.	
SHANDONG NEW TIME PHARMACEUTICAL CO., LTD. NO. 1, NORTH OUTER RING RD.	
· ·	
NO. 1, NORTH OUTER RING RD.	

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	12526692

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.

Email: docket@c-m.com

Correspondent Name: CESARI AND MCKENNA, LLP Address Line 1: 88 BLACK FALCON AVE

Address Line 2: SUITE 271

Address Line 4: BOSTON, MASSACHUSETTS 02210

ATTORNEY DOCKET NUMBER:	218217-0002
NAME OF SUBMITTER:	Y. ROCKY TSAO
SIGNATURE:	/Y. Rocky Tsao/
DATE SIGNED:	03/13/2014

Total Attachments: 2

PATENT
REEL: 032424 FRAME: 0384

source=27N6318#page1.tif source=27N6318#page2.tif

> PATENT REEL: 032424 FRAME: 0385

ASSIGNMENT

Whereas we, Lunan Pharmaceutical Group Corporation, whose address is No. 209, Hongqi Road, Linyi City, Shandong Province, 276006, China, and Fagen Biomedical INC. Chongqing, whose address is 70 Keyuan 4th St., Shiqiaopu District, Chongqing City, 400041, China, the Assignors, for Letters Patent of the United States of America entitled RECOMBINANT CHIMERIC PROTEIN OF NEUTROPHIL INHIBITORY FACTOR AND HIRUGEN, AND PHARMACEUTICAL COMPOSITION THEREOF, the specification of which was filed on February 18, 2008 and accorded Serial No. 12/526,692; and

Whereas Lunan Pharmaceutical Group Corporation and Shandong New Time Pharmaceutical CO., LTD., whose address is No. 1, North Outer Ring Rd., Feixian, Shandong Province, 273400, China and which, together with their successors and assigns, hereinafter called "Assignees," are desirous of co-acquiring the title, rights, benefits, and privileges hereinafter recited;

Now, therefore, for valuable consideration furnished by Assignees to us, receipt and sufficiency of which we hereby acknowledge, without reservation:

- 1. Assign, transfer and convey to Assignees our entire right, title, and interest in and to said inventions and discoveries, said application for Letters Patent of the United States of America, any and all other applications for Letters Patent on said inventions and discoveries in whatsoever countries, including all divisional, renewal, substitute, continuation, continuation-in-part, and Convention applications based in whole or in part upon said inventions or discoveries, or upon said applications, and any and all Letters Patent, reissues, reexaminations, and extensions of Letters Patent granted for said inventions and discoveries or upon said applications, and every priority right that is or may be predicated upon or arise from said inventions, said discoveries, said applications, and said Letters Patent;
- 2. Authorize Assignees to file patent applications in any or all countries on any or all of said inventions and discoveries in our name or in the name of Assignees or otherwise as Assignees may deem advisable, under the International Convention or otherwise;
- 3. Authorize and request the Commissioner of Patents and Trademarks of the United States of America and the empowered officials of all other governments to issue or transfer all said Letters Patent to Assignees, as assignees of the entire right, title, and interest therein or otherwise as Assignees may direct;
- 4. Warrant that we have not knowingly conveyed to others any right in said inventions, discoveries, applications, or patents or any license to use the same or to make, use, or sell anything embodying or utilizing any of said inventions or discoveries; and that we have good right to assign the same to Assignees without encumbrance;

1

5. Bind our heirs, legal representatives and assigns, as well as ourselves, to do, upon Assignees' request and at Assignees' expense, but without additional consideration to us or them, all acts reasonably serving to assure that the said inventions and discoveries, the said patent applications, and the said Letters Patent shall be held and enjoyed by Assignees as fully and entirely as the same could have been held and enjoyed by us, our heirs, legal representatives, and assigns if this assignment had not been made; and particularly to execute and deliver to Assignees all lawful application documents including petitions, specifications, and oaths, and all assignments, disclaimers, and lawful affidavits in form and substance as may be requested by Assignees; to communicate to Assignees all facts known to us relating to said inventions and discoveries or the history thereof; and to furnish Assignees with any and all documents, photographs, models, samples, and other physical exhibits in our control or in the control of our heirs, legal representatives or assigns which may be useful for establishing the facts of our conceptions, disclosures, and reduction to practice of said inventions and discoveries.

In testimony of which we have executed this Assignment on the date indicated next to our names.

February 14, 2014

Lunan Pharmaceutical Group Corporation, Assignor

February 14, 2014

Date

Lunan Pharmaceutical Group Corporation, Assignor

Fagen Biomedical Inc., Chongqing, Assignor